In the AML15 trial, which enrolled 137 core-binding factor AML (CBF-AML) patients, 72 of whom received GO, Burnett et al. were the first to demonstrate an improvement in overall survival (OS), particularly in favorable-risk AML, when GO was added to induction [3]. Here, CEBPZ is linked to acute myeloid leukemia.